Literature DB >> 23055870

Elevated tobramycin concentrations following endotracheal administration in a premature infant.

Amanda Howard-Thompson1, Michael L Christensen.   

Abstract

The following case report describes a 1-month-old, 34-week-gestation premature neonate who had compromised renal function. The neonate received endotracheally administered tobramycin (300 mg every 12 hours) via a PARI PLUS reusable nebulizer to treat a documented Gram-negative tracheostomy infection. The patient also received systemic tobramycin (2.5 mg/kg intravenously every 18 hours). The tobramycin serum concentration obtained 45 hours after the last intravenous dose and 11.5 hours after the second nebulized dose was 17.6 mg/L. The tobramycin nebulizations were stopped.

Entities:  

Keywords:  endotracheal; neonate; tobramycin

Year:  2008        PMID: 23055870      PMCID: PMC3462063          DOI: 10.5863/1551-6776-13.2.88

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  22 in total

Review 1.  Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs.

Authors:  C G Prober; P D Walson; J Jones
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

2.  Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study.

Authors:  J Klastersky; E Huysmans; D Weerts; C Hensgens; D Daneau
Journal:  Chest       Date:  1974-06       Impact factor: 9.410

3.  Endotracheal gentamicin in bronchial infections in patients with tracheostomy.

Authors:  J Klastersky; C Geuning; E Mouawad; D Daneau
Journal:  Chest       Date:  1972-02       Impact factor: 9.410

Review 4.  Environmental factors and developmental outcomes in the lung.

Authors:  Radhika Kajekar
Journal:  Pharmacol Ther       Date:  2007-02-24       Impact factor: 12.310

5.  Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group.

Authors:  R B Brown; J A Kruse; G W Counts; J A Russell; N V Christou; M L Sands
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

Authors:  S S Crosby; W A Edwards; C Brennan; E P Dellinger; L A Bauer
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

7.  Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration.

Authors:  W Odio; E Van Laer; J Klastersky
Journal:  J Clin Pharmacol       Date:  1975-07       Impact factor: 3.126

Review 8.  Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Authors:  Susan M Cheer; John Waugh; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients.

Authors:  Joan R Badia; Dolors Soy; Maria Adrover; Miquel Ferrer; Maria Sarasa; Antonio Alarcón; Carles Codina; Antoni Torres
Journal:  J Antimicrob Chemother       Date:  2004-06-23       Impact factor: 5.790

10.  Endotracheal aminoglycosides in gram negative pneumonia. A preliminary report.

Authors:  V J Sorensen; H M Horst; F N Obeid; B A Bivins
Journal:  Am Surg       Date:  1986-07       Impact factor: 0.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.